BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
NCT00586443
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
56
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
bevacizumab, everolimus, panitumumab
Sponsor
Herbert Hurwitz, MD
Collaborators
[object Object]
[object Object]
[object Object]